NEW YORK, Oct. 14 - Incyte Genomics today said it may spend up to $30 million to buy back its own stock, which it says is undervalued.
Registering provides access to this and other free content.
Already have an account?Login Now.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.